Skip to main content

8 Result(s)

within G. Sassolas Remove this filter

and

  1. No Access

    Article

    Familial pituitary adenomas with a heterogeneous functional pattern: Clinical and genetic features

    Familial pituitary adenoma is a rare syndrome which may present either as isolated lesions, or in association with other endocrine tumors, for example in the frame of multiple endocrine neoplasia (MEN-1) or Ca...

    G. Raverot MD, W. Arnous, A. Calender… in Journal of Endocrinological Investigation (2007)

  2. No Access

    Article

    Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance

    Background. Prolactinomas usually exhibit a benign course and can be safely and effectively managed by dopamine agonists (DA). However, some are locally invasive and may show resistance to DA therapy, and the man...

    E. Delgrange, G. Sassolas, G. Perrin, M. Jan, J. Trouillas in Acta Neurochirurgica (2005)

  3. No Access

    Article

    Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas

    As they are clinically silent, gonadotroph cell pituitary adenomas are usually diagnosed only when pituitary enlargement causes visual impairment or hypopituitarism. In postmenopausal women presenting with pit...

    Ph. Chanson M.D., N. Lahlou, A. Warnet… in Journal of Endocrinological Investigation (1994)

  4. No Access

    Chapter and Conference Paper

    Sandostatin® in Digestive Endocrine Tumors

    Some years ago, several authors reported that the tetradecapeptide somatostatin could be of value for the temporary control of inappropriate secretions from endocrine tumors of the digestive tract [2, 3, 5]. H...

    J. A. Chayvialle, J. C. Souquet, G. Sassolas… in Sandostatin® in the Treatment of Gastroent… (1989)

  5. No Access

    Chapter and Conference Paper

    Effects of Long-Term Administration of Sandostatin® (SMS 201–995) at Increasing Doses in 40 Acromegalic Patients. Results from the French Sandostatin Acromegaly Study Group

    Several studies demonstrate the efficacy of short- and long-term Sandostatin® treatment in acromegaly administered subcutaneously at doses ranging from 150 to 300 µg up to 600 µg per day [1, 3, 5, 7–10]. A rhythm...

    G. Sassolas, P. Fossati, P. Chanson… in Sandostatin® in the Treatment of Acromegaly (1988)

  6. No Access

    Article

    Pharmacokinetics of human growth hormone releasing factor (hGRF-44 NH2) in normal men after intravenous administration of a large range of doses

    Three ranges of doses of growth hormone releasing factor (2.5–80 µg, 80–320 µg and 75–600 µg) were intravenously administered to healthy young volunteers in three double blind studies.

    P. Girard, R. Cohen, G. Sassolas, C. Harthe… in European Journal of Clinical Pharmacology (1987)

  7. Article

    CUSHING'S SYNDROME BY ECTOPIC ACTH SECRETION: EFFECT OF MIFEPRISTONE

    Mifepristone (RU 486 - Roussel-Udlaf), an antiglucorticoid receptor with no agonist activity, has been proposed as treatment of hyper-cortisolism in adults. A 27 month old girl presented a Cushing's syndrome, ...

    B Beaufrère, P Chatelain, G Sassolas, Y Morel, N Catbeh, M Aguercif… in Pediatric Research (1986)

    Download PDF (308 KB)

  8. No Access

    Article

    Synthetic human growth hormone releasing factor (h-GRF-I-44-NH2) dose response effect on growth hormone and prolactin secretion in healthy adult men

    The dose-effect relationship of an i.v. bolus of synthetic h-GRF-44 on growth-hormone and prolactin secretion has been studied. Seven healthy adult volunteers received in a random order h-GRF-44 2.5, 5, 10, 20...

    J. P. Boissel, R. Cohen, S. Biot-Laporte… in European Journal of Clinical Pharmacology (1986)